

**WEBSITE: [www.businessstandard.com](http://www.businessstandard.com)**

EDITION: ONLINE

DATE: 26.07.10

<http://www.business-standard.com/india/news/bilcare%5Cs-consolidated-net-sales-increased-to-rs-104783-cr/402527/>

## **Bilcare's Consolidated Net Sales increased to Rs 1,047.83 cr**

Overseas Net Profit grows by 86.51 percent for the year ended 31st March, 2010

Board of Directors recommends Annual Dividend of 25 percent

Bilcare Ltd. (BSE code: 526853), service provider to the global pharmaceutical industry posted an impressive performance for the year ended March 31st 2010.

The Consolidated Sales for the year ended March 31st 2010, stood at Rs.1047.83 Cr., showing a growth of 22.41 percent as against Rs.856.02 Cr. in the corresponding period of previous year, resulting in EBIDTA of Rs.259.92 Cr. and Net Profit of Rs.116.95 Cr., a growth of 33.83% in EBIDTA and 41.01% in Net Profit.

The Board of Directors of the Company at its meeting held on July 23, 2010, inter alia, has recommended a dividend of Rs. 2.50 per share for the year ended March 31, 2010 subject to the approval of the Members.

Mr. Mohan Bhandari, Chairman & Managing Director, Bilcare Limited announced: "I am delighted to inform you about our steady state growth of established business in pharma packaging innovation and clinical supplies, equally exciting are prospects for our newly launched technology, which has now gone into execution for Delhi State Police Force. It is also being deployed in leading pharmaceutical and agrochemical companies in India. Internationally, this technology has been accepted by a leading wine producer in USA as well as by the Presidential security force of an Asian country. Bilcare is about to close a deal with a European consumer product company. On the document security front, a major trial is underway with a printer manufacturer in USA".

The India Standalone Sales for the quarter end (Q4FY10) stood at Rs.145.71 Cr. as against Rs.121.86 Cr. in the same quarter of the previous year, showing a growth of 19.57%. This resulted in the EBITDA for India Standalone growing to Rs.47.01 Cr. from Rs.37.32 Cr. in the corresponding quarter of the previous year, showing a growth of 25.96%. India standalone Sales for the year ended 31st March 2010, stood at Rs.549.65 Cr. as against Rs.471.33 Cr. of the previous year. EBITDA and Net Profit for the year were at Rs.165.74 Cr. and Rs.75.47 Cr., registering a growth of 26.67 percent in EBIDTA and 24.33 percent in Net Profit.

Overseas Sales for the year ended March 31st 2010, stood at Rs.498.18 Cr. as against Rs.384.69 Cr. of the previous year, showing a growth of 29.50 percent. Similarly, EBIDTA and Net Profit for the year ended at Rs.94.18 Cr. and Rs.41.48 Cr. showing a growth of 48.62 percent in EBIDTA and 86.51 percent in Net Profit.



About Bilcare:

Bilcare is an internationally integrated service provider to the global pharmaceutical industry offering innovative pharma packaging & research, global clinical trial supplies services and anti-counterfeiting technologies for the pharmaceuticals; while Bilcare Technologies under its nonClonableID™ offers identification, authentication and secure track-n-trace technologies. Bilcare operates state-of-the-art manufacturing and research facilities in India, Singapore, USA, UK and has regional offices in Brazil, Germany, China and Australia. Bilcare provides solutions that address many of the industry's key concerns including the Five Key concerns - (5 C's) viz. counterfeit, compliance, communication, convenience and cost.

WEBSITE: [www.profit.ndtv.com](http://www.profit.ndtv.com)

EDITION: ONLINE

DATE: 26.07.10

<http://profit.ndtv.com/news/show/bilcare-net-profit-rises-29-06-in-the-march-2010-quarter-46626>

### **Bilcare net profit rises 29.06% in the March 2010 quarter**

Net profit of Bilcare rose 29.06% to Rs 22.25 crore in the quarter ended March 2010 as against Rs 17.24 crore during the previous quarter ended March 2009. Sales rose 19.57% to Rs 145.71 crore in the quarter ended March 2010 as against Rs 121.86 crore during the previous quarter ended March 2009.

For the full year, net profit rose 24.02% to Rs 75.28 crore in the year ended March 2010 as against Rs 60.70 crore during the previous year ended March 2009. Sales rose 16.62% to Rs 549.65 crore in the year ended March 2010 as against Rs 471.33 crore during the previous year ended March 2009.

WEBSITE: [www.prlog.org](http://www.prlog.org)  
EDITION: ONLINE  
DATE: 26.07.10

<http://www.prlog.org/10817112-bilcares-consolidated-net-sales-increased-to-rs-104783-cr-overseas-net-profit-grows-by-8651.html>

### **Bilcare's Consolidated Net Sales increased to Rs. 1047.83 Cr; Overseas Net Profit grows by 86.51%**

Bilcare Ltd. (BSE code: 526853), service provider to the global pharmaceutical industry posted an impressive performance for the year ended March 31st 2010.

Bilcare's Consolidated Net Sales increased to Rs. 1047.83 Cr;

Overseas Net Profit grows by 86.51 percent for the year ended 31st March, 2010

~ Board of Directors recommends Annual Dividend of 25 percent ~

July 26th 2010, New Delhi: Bilcare Ltd. (BSE code: 526853), service provider to the global pharmaceutical industry posted an impressive performance for the year ended March 31st 2010.

The Consolidated Sales for the year ended March 31st 2010, stood at Rs.1047.83 Cr., showing a growth of 22.41 percent as against Rs.856.02 Cr. in the corresponding period of previous year, resulting in EBIDTA of Rs.259.92 Cr. and Net Profit of Rs.116.95 Cr., a growth of 33.83% in EBIDTA and 41.01% in Net Profit.

The Board of Directors of the Company at its meeting held on July 23, 2010, inter alia, has recommended a dividend of Rs. 2.50 per share for the year ended March 31, 2010 subject to the approval of the Members.

Mr. Mohan Bhandari, Chairman & Managing Director, Bilcare Limited announced: "I am delighted to inform you about our steady state growth of established business in pharma packaging innovation and clinical supplies, equally exciting are prospects for our newly launched technology, which has now gone into execution for Delhi State Police Force. It is also being deployed in leading pharmaceutical and agrochemical companies in India. Internationally, this technology has been accepted by a leading wine producer in USA as well as by the Presidential security force of an Asian country. Bilcare is about to close a deal with a European consumer product company. On the document security front, a major trial is underway with a printer manufacturer in USA".

The India Standalone Sales for the quarter end (Q4FY10) stood at Rs.145.71 Cr. as against Rs.121.86 Cr. in the same quarter of the previous year, showing a growth of 19.57%. This resulted in the EBITDA for India Standalone growing to Rs.47.01 Cr. from Rs.37.32 Cr. in the corresponding quarter of the previous year, showing a growth of 25.96%. India standalone Sales for the year ended 31st March 2010, stood at

Rs.549.65 Cr. as against Rs.471.33 Cr. of the previous year. EBITDA and Net Profit for the year were at Rs.165.74 Cr. and Rs.75.47 Cr., registering a growth of 26.67 percent in EBITDA and 24.33 percent in Net Profit.

Overseas Sales for the year ended March 31st 2010, stood at Rs.498.18 Cr. as against Rs.384.69 Cr. of the previous year, showing a growth of 29.50 percent. Similarly, EBITDA and Net Profit for the year ended at Rs.94.18 Cr. and Rs.41.48 Cr. showing a growth of 48.62 percent in EBITDA and 86.51 percent in Net Profit.

About Bilcare:

Bilcare is an internationally integrated service provider to the global pharmaceutical industry offering innovative pharma packaging & research, global clinical trial supplies services and anti-counterfeiting technologies for the pharmaceuticals; while Bilcare Technologies under its nonClonableID™ offers identification, authentication and secure track-n-trace technologies Bilcare operates state-of-the-art manufacturing and research facilities in India, Singapore, USA, UK and has regional offices in Brazil, Germany, China and Australia. Bilcare provides solutions that address many of the industry's key concerns including the Five Key concerns - (5 C's) viz. counterfeit, compliance, communication, convenience and cost.

WEBSITE: [www.iiflcap.com](http://www.iiflcap.com)

EDITION: ONLINE

DATE: 26.07.10

<http://www.iiflcap.com/FrontPage/NewsInner.aspx?NId=4402069>

**The Board of Directors of the Company at its meeting held on July 23, 2010, inter alia, has recommended a dividend of Rs. 2.50 per share for the year ended March 31, 2010 subject to the approval of the Members.**

Bilcare Ltd. service provider to the global pharmaceutical industry posted an impressive performance for the year ended March 31st 2010.

The Consolidated Sales for the year ended March 31st 2010, stood at Rs10.47bn, showing a growth of 22.41 percent as against Rs8.56bn in the corresponding period of previous year, resulting in EBIDTA of Rs2.59bn and Net Profit of Rs1.16bn., a growth of 33.83% in EBIDTA and 41.01% in Net Profit.

The Board of Directors of the Company at its meeting held on July 23, 2010, inter alia, has recommended a dividend of Rs. 2.50 per share for the year ended March 31, 2010 subject to the approval of the Members.

Mohan Bhandari, Chairman & Managing Director, Bilcare Limited announced: "I am delighted to inform you about our steady state growth of established business in pharma packaging innovation and clinical supplies, equally exciting are prospects for our newly launched technology, which has now gone into execution for Delhi State Police Force.

It is also being deployed in leading pharmaceutical and agrochemical companies in India. Internationally, this technology has been accepted by a leading wine producer in USA as well as by the Presidential security force of an Asian country. Bilcare is about to close a deal with a European consumer product company. On the document security front, a major trial is underway with a printer manufacturer in USA".

The India Standalone Sales for the quarter end (Q4FY10) stood at Rs1.45bn. as against Rs1.21bn in the same quarter of the previous year, showing a growth of 19.57%. This resulted in the EBITDA for India Standalone growing to Rs470mn from Rs.373mn in the corresponding quarter of the previous year, showing a growth of 25.96%.

India standalone Sales for the year ended 31st March 2010, stood at Rs5.49bn as against Rs4.71bn. of the previous year. EBITDA and Net Profit for the year were at Rs1.65bn and Rs754.7mn, registering a growth of 26.67% in EBIDTA and 24.33% in Net Profit.

Overseas Sales for the year ended March 31st 2010, stood at Rs4.98bn as against Rs3.84bn of the previous year, showing a growth of 29.50%. Similarly, EBIDTA and Net Profit for the year ended at Rs941mn and Rs414mn showing a growth of 48.62% in EBIDTA and 86.51% in Net Profit.

WEBSITE: [www.rockingcalls.com](http://www.rockingcalls.com)

EDITION: ONLINE

DATE: 26.07.10

<http://rockingcalls.com/stock-market-results-for-july-26-2010-26072010/>

### **Stock market results for July 26, 2010 (26/07/2010)**

#### **Bilcare RESULTS Q1**

Sales at Rs.145cr vs Rs.121cr ((YoY))

PAT at Rs.22.4cr vs Rs.17.2cr ((YoY))

WEBSITE: www.abnews.in

EDITION: ONLINE

DATE: 26.07.10

<http://abnews.in/bilcare%E2%80%99s-consolidated-net-sales-increased-to-rs-1047-83-cr-overseas-net-profit-grows-by-86-51-percent-for-the-year-ended-31st-march-2010/>

## **Bilcare's Consolidated Net Sales increased to Rs. 1047.83 Cr; Overseas Net Profit grows by 86.51 percent for the year ended 31st March, 2010**

Board of Directors recommends Annual Dividend of 25 percent

Bilcare Ltd. (BSE code: 526853), service provider to the global pharmaceutical industry posted an impressive performance for the year ended March 31st 2010.

The Consolidated Sales for the year ended March 31st 2010, stood at Rs.1047.83 Cr., showing a growth of 22.41 percent as against Rs.856.02 Cr. in the corresponding period of previous year, resulting in EBIDTA of Rs.259.92 Cr. and Net Profit of Rs.116.95 Cr., a growth of 33.83% in EBIDTA and 41.01% in Net Profit.

The Board of Directors of the Company at its meeting held on July 23, 2010, inter alia, has recommended a dividend of Rs. 2.50 per share for the year ended March 31, 2010 subject to the approval of the Members.

Mr. Mohan Bhandari, Chairman & Managing Director, Bilcare Limited announced: "I am delighted to inform you about our steady state growth of established business in pharma packaging innovation and clinical supplies, equally exciting are prospects for our newly launched technology, which has now gone into execution for Delhi State Police Force. It is also being deployed in leading pharmaceutical and agrochemical companies in India. Internationally, this technology has been accepted by a leading wine producer in USA as well as by the Presidential security force of an Asian country. Bilcare is about to close a deal with a European consumer product company. On the document security front, a major trial is underway with a printer manufacturer in USA".

The India Standalone Sales for the quarter end (Q4FY10) stood at Rs.145.71 Cr. as against Rs.121.86 Cr. in the same quarter of the previous year, showing a growth of 19.57%. This resulted in the EBITDA for India Standalone growing to Rs.47.01 Cr. from Rs.37.32 Cr. in the corresponding quarter of the previous year, showing a growth of 25.96%. India standalone Sales for the year ended 31st March 2010, stood at Rs.549.65 Cr. as against Rs.471.33 Cr. of the previous year. EBITDA and Net Profit for the year were at Rs.165.74 Cr. and Rs.75.47 Cr., registering a growth of 26.67 percent in EBIDTA and 24.33 percent in Net Profit.

Overseas Sales for the year ended March 31st 2010, stood at Rs.498.18 Cr. as against Rs.384.69 Cr. of the previous year, showing a growth of 29.50 percent. Similarly, EBIDTA and Net Profit for the year

ended at Rs.94.18 Cr. and Rs.41.48 Cr. showing a growth of 48.62 percent in EBIDTA and 86.51 percent in Net Profit.

#### About Bilcare

Bilcare is an internationally integrated service provider to the global pharmaceutical industry offering innovative pharma packaging & research, global clinical trial supplies services and anti-counterfeiting Technologies for the pharmaceuticals; while Bilcare Technologies under its nonClonableID™ offers identification , authentication and secure track-n-trace technologies Bilcare operates state-of-the-art manufacturing and research facilities in India, Singapore, USA, UK and has regional offices in Brazil, Germany, China and Australia. Bilcare provides solutions that address many of the industry's key concerns including the Five Key concerns – (5 C's) viz. counterfeit, compliance, communication, convenience and cost.

WEBSITE: [www.blish.in.com](http://www.blish.in.com)

EDITION: ONLINE

DATE: 26.07.10

[http://blish.in.com/pharma-india/post/bilcares\\_consolidated\\_net-439539.html](http://blish.in.com/pharma-india/post/bilcares_consolidated_net-439539.html)

### **Bilcare's Consolidated Net Sales increased to Rs. 1047.83 Cr ...**

It is also being deployed in leading pharmaceutical and agrochemical companies in India. Internationally, this technology has been accepted by a leading wine producer in USA as well as by the Presidential security force of an Asian ...

Bilcare's Consolidated Net Sales increased to Rs. 1047.83 Cr; Overseas Net Profit grows by 86.51 percent for the year ended 31st March, 2010

~ Board of Directors recommends Annual Dividend of 25 percent ~

July 26th 2010, New Delhi: Bilcare Ltd. (BSE code: 526853), service provider to the global pharmaceutical industry posted an impressive performance for the year ended March 31st 2010.

The Consolidated Sales for the year ended March 31st 2010, stood at Rs.1047.83 Cr., showing a growth of 22.41 percent as against Rs.856.02 Cr. in the corresponding period of previous year, resulting in EBIDTA of Rs.259.92 Cr. and Net Profit of Rs.116.95 Cr., a growth of 33.83% in EBIDTA and 41.01% in Net Profit.

The Board of Directors of the Company at its meeting held on July 23, 2010, inter alia, has recommended a dividend of Rs. 2.50 per share for the year ended March 31, 2010 subject to the approval of the Members.

Mr. Mohan Bhandari, Chairman & Managing Director, Bilcare Limited announced: "I am delighted to inform you about our steady state growth of established business in pharma packaging innovation and clinical supplies, equally exciting are prospects for our newly launched technology, which has now gone into execution for Delhi State Police Force. It is also being deployed in leading pharmaceutical and agrochemical companies in India. Internationally, this technology has been accepted by a leading wine producer in USA as well as by the Presidential security force of an Asian country. Bilcare is about to close a deal with a European consumer product company. On the document security front, a major trial is underway with a printer manufacturer in USA".

The India Standalone Sales for the quarter end (Q4FY10) stood at Rs.145.71 Cr. as against Rs.121.86 Cr. in the same quarter of the previous year, showing a growth of 19.57%. This resulted in the EBITDA for India Standalone growing to Rs.47.01 Cr. from Rs.37.32 Cr. in the corresponding quarter of the previous year, showing a growth of 25.96%. India standalone Sales for the year ended 31st March 2010, stood at Rs.549.65 Cr. as against Rs.471.33 Cr. of the previous year. EBITDA and Net Profit for the year were at

Rs.165.74 Cr. and Rs.75.47 Cr., registering a growth of 26.67 percent in EBIDTA and 24.33 percent in Net Profit.

Overseas Sales for the year ended March 31st 2010, stood at Rs.498.18 Cr. as against Rs.384.69 Cr. of the previous year, showing a growth of 29.50 percent. Similarly, EBIDTA and Net Profit for the year ended at Rs.94.18 Cr. and Rs.41.48 Cr. showing a growth of 48.62 percent in EBIDTA and 86.51 percent in Net Profit.

About Bilcare:

Bilcare is an internationally integrated service provider to the global pharmaceutical industry offering innovative pharma packaging & research, global clinical trial supplies services and anti-counterfeiting technologies for the pharmaceuticals; while Bilcare Technologies under its nonClonableID™ offers identification, authentication and secure track-n-trace technologies Bilcare operates state-of-the-art manufacturing and research facilities in India, Singapore, USA, UK and has regional offices in Brazil, Germany, China and Australia. Bilcare provides solutions that address many of the industry's key concerns including the Five Key concerns - (5 C's) viz. counterfeit, compliance, communication, convenience and cost.